Journal Article
. 2008 Dec;8().
doi: 10.1186/1471-2407-8-389.

Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients

Marie-Christine W Gast 1 Harm van Tinteren  Marijke Bontenbal  René Q G C M van Hoesel  Marianne A Nooij  Sjoerd Rodenhuis  Paul N Span  Vivianne C G Tjan-Heijnen  Elisabeth G E de Vries  Nathan Harris  Jos W R Twisk  Jan H M Schellens  Jos H Beijnen  
Affiliations
  • PMID: 19108738
  •     36 References
  •     5 citations

Abstract

Background: Better breast cancer prognostication may improve selection of patients for adjuvant therapy. We conducted a retrospective follow-up study in which we investigated sera of high-risk primary breast cancer patients, to search for proteins predictive of recurrence free survival.

Methods: Two sample sets of high-risk primary breast cancer patients participating in a randomised national trial investigating the effectiveness of high-dose chemotherapy were analysed. Sera in set I (n = 63) were analysed by surface enhanced laser desorption ionisation time-of-flight mass spectrometry (SELDI-TOF MS) for biomarker finding. Initial results were validated by analysis of sample set II (n = 371), using one-dimensional gel-electrophoresis.

Results: In sample set I, the expression of a peak at mass-to-charge ratio 9198 (relative intensity <or= 20 or > 20), identified as haptoglobin (Hp) alpha-1 chain, was strongly associated with recurrence free survival (global Log-rank test; p = 0.0014). Haptoglobin is present in three distinct phenotypes (Hp 1-1, Hp 2-1, and Hp 2-2), of which only individuals with phenotype Hp 1-1 or Hp 2-1 express the haptoglobin alpha-1 chain. As the expression of the haptoglobin alpha-1 chain, determined by SELDI-TOF MS, corresponds to the phenotype, initial results were validated by haptoglobin phenotyping of the independent sample set II by native one-dimensional gel-electrophoresis. With the Hp 1-1 phenotype as the reference category, the univariate hazard ratio for recurrence was 0.87 (95% CI: 0.56 - 1.34, p = 0.5221) and 1.03 (95% CI: 0.65 - 1.64, p = 0.8966) for the Hp 2-1 and Hp 2-2 phenotypes, respectively, in sample set II.

Conclusion: In contrast to our initial results, the haptoglobin phenotype was not identified as a predictor of recurrence free survival in high-risk primary breast cancer in our validation set. Our initial observation in the discovery set was probably the result of a type I error (i.e. false positive). This study illustrates the importance of validation in obtaining the true clinical applicability of a potential biomarker.

Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction.
Mahmoud Suleiman, Doron Aronson, +11 authors, Andrew P Levy.
Diabetes, 2005 Aug 27; 54(9). PMID: 16123372
Cancer statistics, 2008.
Ahmedin Jemal, Rebecca Siegel, +4 authors, Michael J Thun.
CA Cancer J Clin, 2008 Feb 22; 58(2). PMID: 18287387
Highly Cited.
Haptoglobin polymorphism and mortality in patients with tuberculosis.
I Kasvosve, Z A Gomo, +8 authors, I T Gangaidzo.
Int J Tuberc Lung Dis, 2000 Aug 19; 4(8). PMID: 10949330
Haptoglobin: function and polymorphism.
J Wassell.
Clin Lab, 2000 Dec 08; 46(11-12). PMID: 11109501
Review.
Haptoglobin phenotype and diabetic nephropathy.
F M Nakhoul, R Zoabi, +6 authors, A P Levy.
Diabetologia, 2001 May 31; 44(5). PMID: 11380078
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study.
Andrew P Levy, Irit Hochberg, +5 authors, Strong Heart Study.
J Am Coll Cardiol, 2002 Dec 12; 40(11). PMID: 12475459
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
Sjoerd Rodenhuis, Marijke Bontenbal, +10 authors, Netherlands Working Party on Autologous Transplantation in Solid Tumors.
N Engl J Med, 2003 Jul 04; 349(1). PMID: 12840087
Discovery-based research and fishing.
David F Ransohoff.
Gastroenterology, 2003 Aug 02; 125(2). PMID: 12891525
Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: curses, caveats, cautions.
R L Somorjai, B Dolenko, R Baumgartner.
Bioinformatics, 2003 Aug 13; 19(12). PMID: 12912828
Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
Bin Ye, Daniel W Cramer, +8 authors, Samuel C Mok.
Clin Cancer Res, 2003 Aug 13; 9(8). PMID: 12912935
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
Aron Goldhirsch, William C Wood, +3 authors, Hans-Jörg Senn.
J Clin Oncol, 2003 Jul 09; 21(17). PMID: 12847142
Highly Cited. Review.
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer.
Ajit Bharti, Patrick C Ma, +4 authors, Ravi Salgia.
Anticancer Res, 2004 May 25; 24(2C). PMID: 15154618
Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients.
Jonathan Tolson, Ralf Bogumil, +9 authors, Thomas Flad.
Lab Invest, 2004 Apr 27; 84(7). PMID: 15107802
Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation.
B H Bowman, A Kurosky.
Adv Hum Genet, 1982 Jan 01; 12. PMID: 6751044
Highly Cited. Review.
Typing and subtyping of haptoglobin from native serum using disc gel electrophoresis in alkaline buffer: application to routine screening.
R P Linke.
Anal Biochem, 1984 Aug 15; 141(1). PMID: 6496936
Nucleotide sequence of the haptoglobin and haptoglobin-related gene pair. The haptoglobin-related gene contains a retrovirus-like element.
N Maeda.
J Biol Chem, 1985 Jun 10; 260(11). PMID: 2987228
Expression of haptoglobin-related protein and its potential role as a tumor antigen.
F P Kuhajda, A I Katumuluwa, G R Pasternack.
Proc Natl Acad Sci U S A, 1989 Feb 01; 86(4). PMID: 2465547    Free PMC article.
Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease.
F P Kuhajda, S Piantadosi, G R Pasternack.
N Engl J Med, 1989 Sep 07; 321(10). PMID: 2475778
Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis.
M C Cid, D S Grant, +3 authors, H K Kleinman.
J Clin Invest, 1993 Mar 01; 91(3). PMID: 7680672    Free PMC article.
Biological and clinical significance of haptoglobin polymorphism in humans.
M R Langlois, J R Delanghe.
Clin Chem, 1996 Oct 01; 42(10). PMID: 8855140
Highly Cited. Review.
Biological functions of haptoglobin--new pieces to an old puzzle.
W Dobryszycka.
Eur J Clin Chem Clin Biochem, 1997 Nov 14; 35(9). PMID: 9352226
Review.
Haptoglobin polymorphism, iron metabolism and mortality in HIV infection.
J R Delanghe, M R Langlois, +9 authors, J Plum.
AIDS, 1998 Jul 14; 12(9). PMID: 9662199
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 Sep 30; 352(9132). PMID: 9752815
Highly Cited.
Bias as a threat to the validity of cancer molecular-marker research.
David F Ransohoff.
Nat Rev Cancer, 2005 Feb 03; 5(2). PMID: 15685197
Highly Cited. Review.
Lessons from controversy: ovarian cancer screening and serum proteomics.
David F Ransohoff.
J Natl Cancer Inst, 2005 Feb 17; 97(4). PMID: 15713968
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Yixin Wang, Jan G M Klijn, +11 authors, John A Foekens.
Lancet, 2005 Feb 22; 365(9460). PMID: 15721472
Highly Cited.
HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples.
Alex J Rai, Craig A Gelfand, +13 authors, Daniel W Chan.
Proteomics, 2005 Jul 30; 5(13). PMID: 16052621
Highly Cited.
Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors.
Gabriel Ricolleau, Catherine Charbonnel, +9 authors, Pascal Jézéquel.
Proteomics, 2006 Feb 14; 6(6). PMID: 16470659
Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
John A Foekens, David Atkins, +17 authors, Yixin Wang.
J Clin Oncol, 2006 Mar 01; 24(11). PMID: 16505412
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).
Gilberto de Castro Junior, Fabio Puglisi, +2 authors, Ahmad Awada.
Crit Rev Oncol Hematol, 2006 Apr 08; 59(1). PMID: 16600618
Review.
Haptoglobin polymorphism in patients with preeclampsia.
Herman T Depypere, Michel R Langlois, +2 authors, Marc Dhont.
Clin Chem Lab Med, 2006 Aug 02; 44(8). PMID: 16879055
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer.
Claudio Belluco, Emanuel F Petricoin, +8 authors, Gordon Whiteley.
Ann Surg Oncol, 2007 Jun 28; 14(9). PMID: 17594124
Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy.
A Gonçalves, B Esterni, +13 authors, J-P Borg.
Oncogene, 2005 Sep 28; 25(7). PMID: 16186794
Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer.
Marie-Christine W Gast, Marc Zapatka, +7 authors, Jos H Beijnen.
J Cancer Res Clin Oncol, 2011 Sep 14; 137(12). PMID: 21913038    Free PMC article.
Proteomic studies in breast cancer (Review).
Xian-Ju Qin, Bruce X Ling.
Oncol Lett, 2012 Jun 29; 3(4). PMID: 22740985    Free PMC article.
Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.
Mariette Labots, Lisette M Schütte, +3 authors, Henk M W Verheul.
Oncologist, 2014 Sep 05; 19(10). PMID: 25187478    Free PMC article.
Systematic Review.
Identification of genes involved in breast cancer and breast cancer stem cells.
Panagiotis Apostolou, Maria Toloudi, Ioannis Papasotiriou.
Breast Cancer (Dove Med Press), 2015 Jul 24; 7. PMID: 26203276    Free PMC article.
Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome.
Laura M L Carvalho, Cláudia N Ferreira, +9 authors, Karina B Gomes.
J Assist Reprod Genet, 2017 Sep 14; 34(12). PMID: 28900795    Free PMC article.